Q-omics provides the consensus-scored FDCSP profile across patient tissues and cancer cell-line models. FDCSP expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FDCSP is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, FDCSP RNA expression shows 14,663 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BRCA, and LSCC as cancer lineages where FDCSP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FDCSP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FDCSP survival associations across molecular data types. FDCSP RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FDCSP RNA expression–survival associations across cancer types. High FDCSP expression shows unfavorable associations in KIRC, LIHC and KIRP, but favorable associations in HNSC, LUSC and LUAD. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FDCSP RNA expression.
This table summarizes FDCSP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for FDCSP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FDCSP shows lower tumor expression in BRCA, COAD, BLCA and HNSC and higher tumor expression in LUAD and STAD. The BRCA box plot shows higher FDCSP RNA expression in normal versus tumor tissue (log2 FC = −3.040, t-test p < 0.001).
This table shows molecular features associated with FDCSP in patient tissues and cancer cell lines. In patient samples, FDCSP shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FDCSP RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LIVER and CNS.
